Baricitinib for Low Platelet Counts After Bone Marrow Transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You had an allogeneic bone marrow or stem cell transplant (from a donor)
- Your platelet count has stayed below 20,000 or you need regular blood transfusions, despite 4+ weeks of standard medications
- You have 'complete donor chimerism' (your new bone marrow is fully working and the donor's blood cells are fully established)
- You don't have active infections, active graft-versus-host disease, cancer relapse, or severe organ problems
- You haven't received a live vaccine in the past 12 weeks and won't during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This trial tests whether adding a drug called baricitinib to your usual TPO-RA treatment works better than TPO-RA alone for people with ITP who haven't responded enough to TPO-RA. It aims to see if the combination helps raise platelet counts and reduce bleeding risk.
This trial studies whether avatrombopag can help your platelet count recover after a bone marrow transplant from an unrelated donor (UCBT) in certain bone marrow failure diseases. If platelets recover better, it may reduce risks related to low platelets after transplant.
This trial tests whether umbilical cord blood can help raise platelet levels in people whose platelets drop after cancer treatment. If it works, it might reduce the need for platelet transfusions and lower bleeding risk.
This trial tests whether baricitinib, a pill that lowers inflammation, can also help reduce blood-clotting risk in people with rheumatoid arthritis. It may help if your arthritis is still active despite current treatment, and you have no other major health conditions.
This study tests whether adding the drug baricitinib to standard clot-removal treatment for a certain type of stroke improves recovery. It aims to see if the drug reduces inflammation in the brain and leads to better outcomes.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.